Samsung Biologics ESG Report Highlights Sustainable Operations and Responsible Growth

Takeaways

• Samsung Biologics' 2026 ESG Report highlights improvements in renewable energy use, carbon reporting, and responsible business practices.
• The company expanded sustainability efforts across its supply chain, strengthened governance, and continued collaborating with the healthcare industry to support long-term climate goals.
• New reporting aligned with global sustainability standards aims to improve transparency for investors, customers, and stakeholders.

Samsung Biologics has released its 2026 ESG Report, outlining the company's progress in environmental, social, and governance (ESG) performance while reinforcing its commitment to sustainable growth and responsible operations.

The annual report details how the global contract development and manufacturing organization (CDMO) is integrating sustainability into its business strategy to meet the growing expectations of customers, investors, and the wider biopharmaceutical industry. As part of its efforts to improve transparency, Samsung Biologics further aligned its disclosures with the European Sustainability Reporting Standards (ESRS) and introduced a dedicated ESG Factbook featuring key sustainability metrics and performance indicators.

A major focus of the report is the company's environmental performance. Samsung Biologics continued advancing its renewable energy transition under its RE100 roadmap, increasing its renewable energy adoption rate to 39.8% during the reporting period.

Read More: Lenovo ESG Report 2024/25 Highlights Sustainability Milestones

The company also strengthened its Scope 3 emissions reporting, expanding coverage from 56.3% to 63.7%. This broader reporting provides greater insight into emissions across its value chain and supports more comprehensive sustainability reporting.

In another environmental milestone, Samsung Biologics received third-party verification for its product carbon footprint (PCF) methodology, improving the credibility of its carbon reporting. The company also earned an 'A' rating in Water Security from the Carbon Disclosure Project (CDP), recognizing its efforts in water management and environmental stewardship.

Beyond environmental initiatives, the report highlights continued investments in people and responsible supply chain management. Samsung Biologics partnered with leading educational institutions to help develop future biotechnology professionals through career development programs. It also expanded leadership and professional growth opportunities for women across the organization.

The company made further progress in supplier engagement, with sustainability assessments covering 57.3% of participating suppliers. The initiative is designed to encourage responsible sourcing practices while building a more resilient and sustainable supply chain.

On the governance front, Samsung Biologics introduced measures to strengthen ethical risk management and improve oversight. According to the report, the company adopted a more diversified evaluation process to enhance the independence, transparency, and credibility of governance decisions, supporting long-term business resilience.

The company also continued working with partners across the healthcare sector to promote broader sustainability goals. As a champion of the Sustainable Markets Initiative (SMI) Health Systems Task Force, Samsung Biologics participated in collaborative projects focused on creating lower-carbon healthcare value chains and encouraging more sustainable industry practices.

Commenting on the report, John Rim, President and CEO of Samsung Biologics, said sustainability remains central to the company's long-term strategy. He noted that continued investments in environmental performance, strong governance, and industry collaboration are intended to strengthen the resilience of the healthcare sector while creating lasting value for stakeholders and patients.

Also Read: Primary TCL Technology ESG Report 2024 Highlights Path to Sustainability

The Samsung Biologics ESG Report reflects the company's ongoing efforts to balance business growth with environmental responsibility, social impact, and sound corporate governance as sustainability becomes an increasingly important priority across the global biopharmaceutical industry.

Follow more news and views via our Reporting & Standards and Featured Articles sections, and stay updated on the top ESG events to attend in 2026 for industry insights and networking.

If you're looking for suitable ESG and Sustainability providers to share customized solutions specific to your business needs, you can check out KnowESG's Solutions page.

If you are an ESG provider looking to get your organization listed on our portal, visit this page.

Source: PR Newswire